In our study, the prevalence of AR expression was 87.5% in SS using a cutoff ≥ 10% and 94.4% with a cut-off ≥1%, which are similar to previous data.28, 43The distribution of AR expression according to BC subtypes using a cutoff ≥ 10% were: 96.8% in Luminal A, 86.2% in Luminal B HER2 negative, 42.8% in TNBC, and 100% in Luminal B HER2 positive. Here, AR is linked to breast cancer.